All In Biotech

Drug Trial Radar · NCT04793139

Efficacy and Safety of Camrelizumab in Real-World Prospective Study

Efficacy and Safety of Camrelizumab for Chinese NSCLC Patients: a Prospective, Observational, Multicenter Real-World Study

Last checked: Nov 20, 2026Latest source record: Mar 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Apr 1, 2021

Primary completion

Jun 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Guangdong Association of Clinical TrialsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 11, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • CamrelizumabDrug

    Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE,Grade 3-5Time frame: From April 1, 2021 to Septeember 30, 2024

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.